

**Amendments to the Claims:**

The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (previously presented) A method for impairing movement of a cutaneous lymphocyte-associated antigen<sup>+</sup> (CLA<sup>+</sup>) memory T-cell within or to the skin of a mammal, said method comprising administering to said mammal an effective amount of an antibody against cutaneous-T-cell-attracting chemokine (CTACK), whereby administration of said antibody impairs movement of said cutaneous lymphocyte-associated antigen<sup>+</sup> memory T-cell within or to the skin of said mammal.

Claim 2 (canceled)

Claim 3 (previously presented) The method of Claim 1, wherein said movement is within said skin.

Claim 4 (previously presented) The method of Claim 1, wherein said antibody neutralizes cutaneous-T-cell-attracting chemokine.

Claims 5-21 (canceled)

Claim 22 (currently amended) A method for treating a patient suffering from a skin disorder selected from the group consisting of allergic-contact dermatitis, psoriasis, wound healing, and carcinoma comprising administering an effective amount of an antibody against cutaneous-T-cell-attracting chemokine.

Claim 23 (canceled)

Claim 24 (currently amended) The method of Claim 1, wherein said administering is local; ~~systemic, topical, subcutaneous, intradermal, or transdermal.~~

Claim 25 (previously presented) The method of Claim 1, wherein said cutaneous lymphocyte-associated antigen<sup>+</sup> memory T-cell moves into the dermis or epidermis of said skin.

Claim 26 (canceled)

Claim 27 (previously presented) The method of Claim 22, wherein said skin disorder is allergic-contact dermatitis.

Claim 28 (previously presented)      The method of Claim 22, wherein said skin disorder is psoriasis.

Claim 29 (previously presented)      The method of Claim 22, wherein said skin disorder is wound healing.

Claim 30 (canceled)

Claim 31 (previously presented)      The method of Claim 22, wherein said skin disorder is carcinoma.

Claim 32 (canceled)

Claim 33 (canceled)

Claim 34 (new)                      The method of Claim 1, wherein said administering is systemic.

Claim 35 (new)                      The method of Claim 1, wherein said administering is topical.

Claim 36 (new)                      The method of Claim 1, wherein said administering is subcutaneous.

Claim 37 (new)                      The method of Claim 1, wherein said administering is intradermal.

Claim 38 (new)                      The method of Claim 1, wherein said administering is transdermal.